Galmed Pharmaceuticals Granted New Patent for Combination of Aramchol and Rezdiffra (Resmetirom) for MASH Treatment
I'm PortAI, I can summarize articles.
Galmed Pharmaceuticals Ltd. announced the grant of new use patents for combining its drug Aramchol with Madrigal Pharmaceuticals’ Rezdiffra for MASH treatment. The patent, granted in South Korea, extends Aramchol’s U.S. patent protection until July 2042, strengthening its position in combination therapies for MASH.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Reuters The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments